But Dempster says its increasing adoption hasn't led to the patching of old bugs.

FORBES: VoIP Vandals

Oritavancin has gone through several drugmakers, including InterMune, and was rejected basically because too much of its pivotal data is years old, from before resistant bugs were much of a problem.

FORBES: The Antibiotics I Missed